Drug Diversion Monitoring 2019
An Early Look at Emerging vs. Established Technology

Established Vendors

Omnicell Analytics: Most-Adopted Emerging Solution, but Many Hamstrung without EMR Integration

Omnicell Analytics is the emerging solution with the most adoption (mostly from former Pandora Analytics clients). Similar to other customer bases, Omnicell Analytics customers with EMR integration report having more comprehensive visibility into dispensing behavior. However, because EMR integration costs extra, a significant number of customers do not have it, are thus unable to drive expected outcomes, and resort to manual processes that result in a higher number of false positives. Omnicell’s Pandora customers tend to be more satisfied than Omnicell Analytics customers—though the older system is more manual and less advanced, it still functions as expected.

Most Medacist RxAuditor Customers Dissatisfied with Manual Investigation Workflows

Medacist RxAuditor clients report dated technology and clunky investigation workflows as key issues hindering effective drug diversion monitoring. By far the largest vendor in the market, Medacist offers several tools intended to provide advanced capabilities, but very few respondents report having or using these tools. Most say their system relies solely on dispensing data from cabinets and carousels and generates lengthy reports that flag abnormal behaviors. While these reports include a wealth of information, respondents are frustrated at having to spend significant time manually weeding out false positives and identifying true diversion. Due to these challenges, 5 of the 16 interviewed RxAuditor customers report the solution is not part of their long-term plans and are turning to other vendors for technology that better supports investigation. Medacist is beta testing a new solution, RxAuditor Investigate, to address product gaps.

Emerging Vendors

Kit Check (Limited Data) Shows Early Signs of Consistent Next-Gen Experience and Improved Accuracy

Kit Check has expanded on their existing kit/tray management customer base with their new drug diversion monitoring solution, Bluesight for Controlled Substances; to date, fewer than 20 organizations are live on the solution. Early data on Kit Check suggests customers are having a strong experience overall. Respondents report Kit Check sets clear expectations and provides rigorous training, helping them overcome the learning curve involved in setting up the right criteria and interfaces to optimize system accuracy and limit false positives. Due to their small customer base, Kit Check also nimbly responds to customer development requests. Respondents report they have EMR and other types of integration, giving them a complete picture of dispensing behavior for investigation. The system is also easy to use and includes tools that help users document investigation findings.

Emerging Solutions Still Vying for Purchase Energy

Other emerging options are also getting consideration, though adoption to date is limited. BD’s new offering—HealthSight Diversion Management—has potential for high adoption given BD’s existing pharmacy customer base. Without existing pharmacy customers, new third-party entrants HelioMetrics, Invistics, and Protenus (each with a handful of live customers) face bigger adoption hurdles since most pharmacies are looking to consolidate to fewer vendors
to improve integration.

Drug Diversion Monitoring Vendor Scope